GSK Signs US$1.5 B ADC Licensing Pact with Hansoh Pharma
By Lalit Mishra
Pharma Deals Review: Vol 2023 Issue 10 (Table of Contents)
Published: 27 Oct-2023
DOI: 10.3833/pdr.v2023.i10.2827 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In a significant move towards bolstering its oncology portfolio, GSK has entered into an exclusive license agreement with Hansoh Pharma for HS-20089, a B7-H4 targeted antibody-drug conjugate (ADC) currently in Phase I clinical trials in China for the treatment of ovarian and endometrial cancer...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS